Biological effects of electric and magnetic fields of extremely low frequency / door 385194 Sheppard, Asher R., Eisenbud, Merril

Thyrotoxicosis with pegylated interferon alfa-2b. door Lowndes, SA, Asher, R, Middleton, MR

Field and Temperature Gradients from Short Conductors in a Dissipative Medium door Quirino Balzano, Kenneth R. Foster, Asher R. Sheppard

Volledige tekst

Patient-delivered tDCS on chronic neuropathic pain in prior responders to TMS (a randomized controlled pilot study) door O'Neill F, Sacco P, Bowden E, Asher R, Burnside G, Cox T, Nurmikko T

Volledige tekst

Sentinel node status predicts survival in thick melanomas: The Oxford perspective door Rughani, MG, Swan, M, Adams, T, Marshall, A, Asher, R, Cassell, O, Middleton, MR

Sentinel node status predicts survival in thick melanomas: the Oxford perspective. door Rughani, MG, Swan, M, Adams, T, Marshall, A, Asher, R, Cassell, O, Middleton, MR

Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. door De Santo, C, Arscott, R, Booth, S, Karydis, I, Jones, M, Asher, R, Salio, M, Middleton, M, Cerundolo, V

Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention? door Morton, RL, Asher, R, Peyton, E, Tran, A, Smit, AK, Butow, PN, Kimlin, MG, Dobbinson, SJ, Wordsworth, S, Keogh, L, Cust, AE

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. door Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide door Ramcharan, R, Petnga Kamdoum, W, Gao, S, Aleksic, T, Pfister, S, Tanner, J, Bridges, E, Asher, R, Watson, A, Margison, G, Woodcock, M, Repapi, E, Li, J, Middleton, M, Macaulay, V

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma door Gupta, A, Love, S, Schuh, A, Collins, L, Thomason, A, Asher, R, Lisle, R, Churchman, M, Shanyinde, M, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Larkin, J, Middleton, MR

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma door Gupta, A, Towers, C, Willenbrock, F, Brant, R, Hodgson, DR, Sharpe, A, Smith, P, Cutts, A, Schuh, A, Asher, R, Myers, K, Love, S, Collins, L, Wise, A, Middleton, MR, Macaulay, VM

Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis door Al Moussawi, K, Chung, K, Carroll, TM, Osterburg, C, Smirnov, A, Lotz, R, Miller, P, Dedeić, Z, Zhong, S, Oti, M, Kouwenhoven, EN, Asher, R, Goldin, R, Tellier, M, Murphy, S, Zhou, H, Dötsch, V, Lu, X

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. door Gao, S, Bajrami, I, Verrill, C, Kigozi, A, Ouaret, D, Aleksic, T, Asher, R, Han, C, Allen, P, Bailey, D, Feller, S, Kashima, T, Athanasou, N, Blay, J, Schmitz, S, Machiels, J, Upile, N, Jones, T, Thalmann, G, Ashraf, S, Wilding, J, Bodmer, W, Middleton, MR, Ashworth, A, Lord, C

Open data and digital morphology door Davies, T, Rahman, I, Lautenschlager, S, Cunningham, J, Asher, R, Barrett, P, Bates, K, Bengtson, S, Benson, R, Boyer, D, Braga, J, Bright, J, Claessens, L, Cox, P, Dong, X, Evans, A, Falkingham, P, Friedman, M, Garwood, R, Goswami, A, Hutchinson, J, Jeffery, N, Johanson, Z, Lebrun, R, Martínez-Pérez, C, Marugán-Lobón, J, O’Higgins, P, Metscher, B, Orliac, M, Rowe, T, Rücklin, M, Sánchez-Villagra, M, Shubin, N, Smith, S, Starck, J, Stringer, C, Summers, A, Sutton, M, Walsh, S, Weisbecker, V, Witmer, L, Wroe, S, Yin, Z, Rayfield, E, Donoghue, P